Help-Medical.Net

Today OptiNose Inc. announced the glaring results of a office evaluating the efficacy of fluticasone when delivered large the Company’s best-seller bi-directional technology in patients with refractory dyed in the wool rhinosinusitis (CRS). The results of the con participate in been published in an article in the September exit of Rhinology.

“Preliminary efficacy of fluticasone delivered during a creative tool in obstinate long-standing Read the rest of this entry »

“We are wound up to story prolonged suffering help in this philosophical people with dangerous unmet medical needfulness. It is gratifying in behalf of our absolute side to secure captivated NP2 Enkephalin and the NTDDS dais from the bench to the bedside and shot these encouraging results”

Diamyd Medical

Durable and level reduction in nuisance scores were reported in the halfway point and apex quantity cohorts of Diamyd Read the rest of this entry »

Amgen (Nasdaq: AMGN) wish judge the results from FREEBIE BEHAVIOUR TOWARDS (the Stab to Cut back Cardiovascular Events with Aranesp® Cure and discretion deliberate over how these results brief the nick run out of of erythropoiesis-stimulating agents (ESAs) representing persistent renal incompetent (CRF) patients at today’s congress of the Nutriment and Medicine Administration’s (FDA) Cardiovascular and Renal Drugs Admonitory Commission (CRDAC). Read the rest of this entry »

Archimedes Pharma, an emerging specialty pharma retinue focused on oncology, trouble, neurology and deprecating nurse sectors, today announced declaration of results from a Remove III, long-term refuge, tolerability and consistency of make, clinical investigation of fentanyl pectin nasal distribute (FPNS) in the treatment of breakthrough cancer torment (BTCP).

The article, entitled "Long-term refuge, tolerability, and consistency Read the rest of this entry »

Acceleron Pharma, Inc., a biopharmaceutical group developing untried therapeutics that soften the spread of cells and tissues including muscle, bone, corpulence, red blood cells and the vasculature, today announced groundwork results from a Condition 1b mug up to assess the cover, tolerability and pharmacodynamic (PD) job of ACE-031 following multiple ascending doses in hale and hearty postmenopausal volunteers. ACE-031 is an investigational Read the rest of this entry »

Outset Pharmaceuticals, Inc. (Nasdaq:THLD) today announced interim results from an running Usher in 1/2 clinical distress in diversified true tumors interrelated to its hypoxia-activated prodrug, TH-302. The results were presented at the European Institute allowing for regarding Medical Oncology (ESMO) Annual Confluence being held in Milan, Italy.

Today’s display focused on possibly man clinical enquiry, the 402 burr under the saddle. Read the rest of this entry »

Isotechnika Pharma Inc. announces that the results of the CONFIRM1 clinical bur conducted particularly its medical implement mate, Atrium Medical Corporation, were presented largely Glenn Van Langenhove, MD, PhD (Middelheim Asylum in Antwerp, Belgium), the ceo investigator, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Painstaking Symposium in Washington, DC keep on week. The CONFIRM1 provisional was conducted to quantify Atrium’s Read the rest of this entry »

Array BioPharma Inc. (NASDAQ: ARRY) today announced unmistakeable interim results of its unusual, enunciated HER2 (ErbB2) inhibitor, ARRY-380, in a Look 1 trial run in patients with advanced cancer. These results are being presented at the 2010 ASCO Titty Cancer Symposium in Country-wide Harbor, Maryland. The be involved in circular (#A7) entitled, "A Condition 1 About to Assess the Safeness, Tolerability and Pharmacokinetics of ARRY-380 Read the rest of this entry »

Argos Therapeutics announced that its Arcelis immunotherapy in the direction of renal stall carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and sanctuary in claque with sunitinib, based upon updated results from an persistent Gradually eliminate 2 venture.

The interim materials demonstrated irrefutable median PFS results in unfavorable peril, newly diagnosed, metastatic RCC (mRCC) patients. The median Read the rest of this entry »

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical assemblage focused on discovering, developing and commercializing cancer therapeutics, today announced that thitherto reported results from its Form 2 burn the midnight oil evaluating tivozanib for the purpose the treatment of advanced renal stall carcinoma (RCC) liking be presented at the Ninth Global Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010. Additionally, Read the rest of this entry »